Trials / Completed
CompletedNCT05794204
RMP-A03 Ocular Suspension in Patients With Pterygium
A Phase 2a Study Evaluating the Safety and Efficacy of RMP-A03 Ocular Suspension in Patients With Pterygium
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 77 (actual)
- Sponsor
- Suzhou Raymon Pharmaceuticals Company, Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to test the safety and efficacy of an ocular medication on the treatment of pterygium.
Detailed description
Following informed consent, patients with pterygium who meet all eligibility criteria will be randomized to an 84-day double-blinded study to measure the safety and efficacy of the study drug as compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RMP-A03 - Dose 1 | Patients will randomized to low dose of RMP-A03 |
| DRUG | RMP-A03 - Dose 2 | Patients will be randomized to high dose of RMP-A03 |
| DRUG | RMP-A03 Placebo | Patients will be randomized to RMP-A03 Placebo |
Timeline
- Start date
- 2023-06-09
- Primary completion
- 2024-01-12
- Completion
- 2024-01-12
- First posted
- 2023-04-03
- Last updated
- 2024-12-06
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05794204. Inclusion in this directory is not an endorsement.